NCT02810951View on ClinicalTrials.gov

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

September 29, 2020

Study Completion Date

April 18, 2022

Conditions
Epidermolysis Bullosa Dystrophica, Recessive
Interventions
GENETIC

FCX-007

FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.

Trial Locations (2)

80045

Children's Hospital Colorado, Aurora

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Castle Creek Biosciences, LLC.

INDUSTRY